Enodia Therapeutics and Pfizer struck a research collaboration and licensing agreement to discover and develop small-molecule Sec61 inhibitors. Enodia will run discovery, optimization, and development activities across multiple collaboration targets using its platform for selective Sec61 translocon modulation, a targeted protein synthesis approach intended to limit systemic effects. Under the deal, Pfizer takes over all clinical, manufacturing, regulatory, and commercial responsibilities after the collaboration term. Enodia will receive an upfront payment and is eligible for milestones plus tiered royalties that could bring total potential value above $500 million. The announcement also positions Sec61 as an enabling node for targeted protein degradation and early-stage pathway control—an area drawing increased interest as companies seek ways to selectively affect disease-driving proteins while preserving essential cellular functions. Enodia previously purchased assets from Kezar Life Sciences tied to a Sec61 discovery and development program, and the reported collaboration is framed as an extension of that work into a joint pharmaceutical path.